查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1365783

糖尿病肾臟病市场：依药物类别、类型、配销通路：2022-2031 年全球机会分析与产业预测

Diabetic nephropathy Market By Drugs Class, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3个工作天内

价格

2021年糖尿病肾臟病变市场价值为19亿美元，预计2022年至2031年年复合成长率为6%，到2031年将达33亿美元。

糖尿病肾臟病是一种体内糖水平长期居高不下的代谢性疾病。糖尿病有两种类型：1 型和 2 型。糖尿病肾臟病是一种糖尿病影响肾臟的疾病，导致慢性肾臟病和肾臟损伤。糖尿病肾臟病是糖尿病患者死亡率和发病率最重要的併发症之一。肾臟病影响肾臟排放体内废物和多余水分的能力。预防或延缓糖尿病肾臟病变的最佳方法是保持健康的生活方式并妥善管理糖尿病和高血压。肾臟疾病可进展为肾衰竭，也称为末期肾功能衰竭。肾衰竭是一种危及生命的疾病。在此阶段，治疗选择包括透析或肾臟移植。

糖尿病肾病变市场-IMG1

糖尿病肾臟病通常是在常规检查中诊断出来的，这是糖尿病管理的一部分。用于诊断糖尿病肾臟病变的常规检查包括尿液白蛋白检查、白蛋白/肌酸酐比值、肾小球滤过率（GFR），以及影像检查（电脑断层扫描、MRI）和切片检查等专门检查。

糖尿病肾臟病变的治疗对于患者来说是非常必要的。治疗糖尿病肾臟病的第一步是治疗和控製糖尿病和高血压。这包括用餐、生活方式的改变、运动、处方药、血压控制药物、血糖控制药物、G蛋白偶联受体（GPCR）药物和抗氧化发炎调节药物。此外，对于晚期糖尿病肾病变也进行肾臟透析、移植和症状治疗。糖尿病肾臟病市场正在快速成长。推动糖尿病肾臟病变市场成长的主要因素包括患有糖尿病的老年人口的增加、糖尿病人口的增加以及各种肾臟疾病发病率的上升。例如，根据《营养与代谢杂誌》报告，埃塞俄比亚西北部贡德尔大学总医院的一项研究发现，糖尿病肾臟病变的盛行率为每10,000名患者中有14例（95%置信区间为10.8至17.7） 。此外，63 名 (13.6%) 糖尿病 (DM) 患者出现糖尿病肾臟病。患有心臟疾病和贫血的第二型糖尿病患者患糖尿病肾臟病的风险增加。因此，这些因素正在推动市场成长。

例如，根据国家糖尿病统计最新报告，2017年至2020年，美国有3730万人患有糖尿病（占美国人口的11.3%），其中确诊人数为2870万人，其中成年人为2850万人，糖尿病患者为850 万人。（23.0% 的成人） 未确诊。

此外，糖尿病和慢性肾臟病的迅速增加导致糖尿病肾臟病变的肾臟病，进一步需要抗糖尿病肾臟病药物。血管张力素转化酵素抑制剂是治疗糖尿病肾臟病的热门药物。 2型糖尿病是最受欢迎的糖尿病肾臟病，吸引了客户的关注，并正在推动糖尿病肾臟病变市场的成长。此外，技术进步、各种产品发布以及主要企业之间的策略（例如收购、联盟和协议）正在推动糖尿病肾臟病市场。例如，阿斯特捷利康公司 (AstraZeneca Plc.) 的 Forxiga 在日本和欧洲获得核准，作为维持强劲竞争和改善产品系列的关键发展策略。

然而，由于不利的报销和併发症发生率，更严格的法规标准和更长的药物核准期限制了市场成长。糖尿病肾臟病变缺乏综合治疗方法也限制了糖尿病肾臟病变市场的成长。

此外，由于糖尿病和肥胖症盛行率上升、药物研发和药物开发的研发投资增加以及人们对糖尿病和肾臟相关疾病的认识不断提高，预计医疗业务将出现成长。因此，预计主要企业在预测期内将获得投资该市场的丰厚机会。

糖尿病肾臟病变市场按药物类别、类型、配销通路和地区进行细分。依药物类别分为血管收缩素转化酵素抑制剂、血管收缩素受体拮抗、钙通道拮抗、利尿剂、肾素抑制剂等。按类型划分，市场分为第 1 型糖尿病和第 2 型糖尿病。按配销通路分为医院药房、线上供应商、药局和零售药房。依地区划分，市场分为北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、欧洲其他地区）、亚太地区（日本、中国、澳洲、印度、韩国、其他地区） ） 、亚太地区（巴西、中国、阿拉伯、澳洲、印度、韩国和南美洲其他地区）。

本报告介绍的主要企业包括雅培实验室、艾伯维公司、阿斯特捷利康公司、拜耳公司、礼来公司、默克公司、诺华公司、辉瑞公司、Reata Pharmaceuticals, Inc.、赛诺菲。

目录

第1章简介

第2章执行摘要

第3章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 糖尿病老年人口快速增加，慢性肾臟病、肥胖及高血压盛行率上升
      • 提高对糖尿病肾臟病的认识和诊断测试
    • 抑制因素
      • 法规规则严格，药品核准时间长
    • 机会
      • 糖尿病肾臟病联合治疗的增加
      • 增加药物研发与开发的研发投入
  • COVID-19 市场影响分析

第4章糖尿病肾臟病变市场：依药物类别

  • 概述
  • 血管收缩素转化酵素抑制剂
  • 血管收缩素受体阻断剂
  • 钙拮抗
  • 利尿剂
  • 肾素抑制剂
  • 其他的

第5章糖尿病肾臟病变市场：依类型

  • 概述
  • 1型糖尿病
  • 2型糖尿病

第6章糖尿病肾臟病市场：依配销通路

  • 概述
  • 医院药房
  • 线上提供者
  • 药局和零售药房

第7章糖尿病肾臟病变市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第8章竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争仪表板
  • 竞争热图
  • 2021年主要企业定位

第9章公司简介

  • AbbVie Inc.
  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co
  • Astrazenica Plc
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals
  • Sanofi
Product Code: A16604

According to a new report published by Allied Market Research, titled, "Diabetic nephropathy Market," The diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.The diabetic nephropathy market is expected to reach $3,338.50 million by 2031. Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.

Diabetic nephropathy Market - IMG1

Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.

Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8-17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.

For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.

Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.

Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Product Benchmarking / Product specification and applications
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Hospital Pharmacy
  • Online Providers
  • Drug Stores and Retail Pharmacy

By Drugs Class

  • Angiotensin-converting Enzyme Inhibitors
  • Angiotensin Receptor Blockers
  • Calcium Channel Blocker
  • Diuretics
  • Renin Inhibitor
  • Others

By Type

  • Type-1 Diabetes
  • Type-2 Diabetes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Abbott Laboratories
    • Astrazenica Plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Sanofi
    • Novartis AG
    • Merck & Co
    • AbbVie Inc.
    • Reata Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension
      • 3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests
    • 3.4.2. Restraints
      • 3.4.2.1. Strict regulatory rules and lengthy drug approval times
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in use of combination therapy for diabetic nephropathy
      • 3.4.3.2. Increase in R&D investments in drug discovery and development
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Angiotensin-converting Enzyme Inhibitors
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Angiotensin Receptor Blockers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Calcium Channel Blocker
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Diuretics
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Renin Inhibitor
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Others
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country

CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Type-1 Diabetes
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Type-2 Diabetes
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacy
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drugs Class
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drugs Class
      • 7.2.5.1.3. Market size and forecast, by Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drugs Class
      • 7.2.5.2.3. Market size and forecast, by Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drugs Class
      • 7.2.5.3.3. Market size and forecast, by Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drugs Class
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drugs Class
      • 7.3.5.1.3. Market size and forecast, by Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drugs Class
      • 7.3.5.2.3. Market size and forecast, by Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. U.K.
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drugs Class
      • 7.3.5.3.3. Market size and forecast, by Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drugs Class
      • 7.3.5.4.3. Market size and forecast, by Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drugs Class
      • 7.3.5.5.3. Market size and forecast, by Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drugs Class
      • 7.3.5.6.3. Market size and forecast, by Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drugs Class
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drugs Class
      • 7.4.5.1.3. Market size and forecast, by Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drugs Class
      • 7.4.5.2.3. Market size and forecast, by Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drugs Class
      • 7.4.5.3.3. Market size and forecast, by Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drugs Class
      • 7.4.5.4.3. Market size and forecast, by Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drugs Class
      • 7.4.5.5.3. Market size and forecast, by Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drugs Class
      • 7.4.5.6.3. Market size and forecast, by Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drugs Class
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drugs Class
      • 7.5.5.1.3. Market size and forecast, by Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drugs Class
      • 7.5.5.2.3. Market size and forecast, by Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drugs Class
      • 7.5.5.3.3. Market size and forecast, by Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drugs Class
      • 7.5.5.4.3. Market size and forecast, by Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Abbott Laboratories
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Bayer AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Eli Lilly and Company
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Merck & Co
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Astrazenica Plc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Pfizer Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Reata Pharmaceuticals
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Sanofi
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 97. BAYER AG: KEY EXECUTIVES
  • TABLE 98. BAYER AG: COMPANY SNAPSHOT
  • TABLE 99. BAYER AG: PRODUCT SEGMENTS
  • TABLE 100. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 105. MERCK & CO: KEY EXECUTIVES
  • TABLE 106. MERCK & CO: COMPANY SNAPSHOT
  • TABLE 107. MERCK & CO: PRODUCT SEGMENTS
  • TABLE 108. MERCK & CO: PRODUCT PORTFOLIO
  • TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES
  • TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT
  • TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS
  • TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO
  • TABLE 113. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 117. PFIZER INC.: KEY EXECUTIVES
  • TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 125. SANOFI: KEY EXECUTIVES
  • TABLE 126. SANOFI: COMPANY SNAPSHOT
  • TABLE 127. SANOFI: PRODUCT SEGMENTS
  • TABLE 128. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. DIABETIC NEPHROPATHY MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF DIABETIC NEPHROPATHY MARKET,2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC NEPHROPATHY MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 17. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 24. DIABETIC NEPHROPATHY MARKET BY REGION, 2021(%)
  • FIGURE 25. U.S. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. CANADA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. MEXICO DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. GERMANY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. FRANCE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. U.K. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. ITALY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. SPAIN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. JAPAN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. CHINA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. INDIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. BRAZIL DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48. COMPETITIVE DASHBOARD
  • FIGURE 49. COMPETITIVE HEATMAP: DIABETIC NEPHROPATHY MARKET
  • FIGURE 50. TOP PLAYER POSITIONING, 2021
  • FIGURE 51. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. REATA PHARMACEUTICALS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 67. REATA PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)